Advances in the biology and treatment of Waldenström's macroglobulinemia: A report from the 5th international workshop on Waldenström's macroglobulinemia, Stockholm, Sweden

Clinical Lymphoma and Myeloma

Volumn 9, Issue 1, 2009, Pages 10-15

  Treon, Steven ^a   Patterson, Christopher ^a   Kimby, Eva ^b   Stone, Marvin ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BENDAMUSTINE; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; FLUDARABINE; HCD 122; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN; INTERLEUKIN 6; LENALIDOMIDE; MONOCLONAL ANTIBODY; NUCLEOSIDE ANALOG; PANOBINOSTAT; PEFLOXACIN; PERIFOSINE; PREDNISONE; RANTES; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALINOSPORAMIDE A; SGN 40; SGN 70; STEROID; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER INCIDENCE; CHROMOSOME 6Q; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOKINE RELEASE; EVOLUTIONARY ADAPTATION; FEBRILE NEUTROPENIA; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HEPATITIS C; HERPES ZOSTER; HUMAN; MONOCLONAL IMMUNOGLOBULINEMIA; NEUROPATHY; NONHODGKIN LYMPHOMA; PATHOGENESIS; PLASMAPHERESIS; SWEDEN; UNITED STATES; UNSPECIFIED SIDE EFFECT; WALDENSTROEM MACROGLOBULINEMIA; PATHOLOGY;

HUMANS; WALDENSTROM MACROGLOBULINEMIA;

EID: 67649525702     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.001     Document Type: Editorial

References (61)

1. Kyle RA, Benson, JT, Larson D, et al. IgM Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Waldenström's Macroglobulinemia (SWM). Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 103)
2. McMaster ML, Goldin L, Csako G, et al. The relationship between Waldenström macroglobulinemia and IgM monoclonal gammopathy of undetermined significance: studies of high-risk families. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 105).
3. Treon SP, Hunter Z, Aggarwal A, et al. Characterization of familial Waldenström's Macroglobulinemia. Ann Oncol 2006; 17:488-94.
4. Kristinsson SY, Björkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström's Macroglobulinemia patients: A population-based study in Sweden. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 106).
5. Hunter ZR, Ioakimidis L, Soumerai J, et al. Increased prevalence of monoclonal gammopathy, abnormal immunoglobulin levels, and recurrent infections in family members of patients with Familial Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's macroglobulinemia, Stockholm, Sweden 2008 (Abstract 107).
6. Landgren O, Gridley G, Engels EA, et al. Chronic immune stimulation and subsequent Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 118).
7. Giordano T. Role of hepatitis C in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 117).
8. Leleu X, O'Connor K, Ho AW, et al. Hepatitis C infection is not associated with Waldenström's Macroglobulinemia. Am J Hematol 2007; 82:83-4.
9. Sahota SS, Babbage G, Weston N. CD27 in defining B-cell memory origins in Waldenström's macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 109).
10. Garcia-Sanz R, Martin-Jimenez P, Ocio EM, et al. Immunoglobulin gene rearrangements in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 113).
11. Braggio E, Fonseca R. NF-kB abnormalities in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 112).
12. Adamia S, Amin S, Patterson CJ, et al. High-throughput microRNA profiling: Identification of miRNA with a potential pathogenetic role in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 114).
13. Rocarro AM, Sacco A, Chen C, et al. MicroRNA expression in the biology, prognosis and treatment of Waldenström's Macroglobulinemia. Blood 2008; Epub ahead of print.
14. Xu L, Ciccarelli B, Hatjiharissi E, et al. 5-azacytidine inhibits the mammalian target of rapamycin complex 1 signal and induces apoptosis in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 115).
15. O'Connor OA. The merging role of histone deacetylase inhibitors in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 137).
16. Jia X, Roccaro AM, Azab A, et al. The novel hydroxamic acid-derived HDAC inhibitor LBH589, induces in vitro anti-tumor activity in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 159).
17. Sun J, Xu L, Tseng HY, et al. Histone deacetylase inhibitors demonstrate significant preclinical activity as single agents, and in combination with bortezomib in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 160).
18. Hatjiharissi E, Mitsiades CS, Li C, et al. Gene expression profiling of malignant and microenvironmental cels in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 119).
19. Ansell SM. Role of CCL5 and Interleukin 6 in the biology of Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 116).
20. Joshua DE, Brown RD, Sze Sulin DMY, et al. T cell immunity in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 123).
21. LeBlond V, Tamburini J, Levy V, et al. Incidence of disease transformation and development of MDS/AML in 165 patients with Waldenström's Macroglobulinemia treated with fludarabine based regimen in three studies (French cooperative group on CLL/WM). Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 149).
22. Leleu X, Soumerai J, Rocarro A, et al. Increased incidience of transformation and myelodysplasia/acute leukemia in patients with Waldenström's Macroglobulinemia treated with nucleoside analogues. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 150).
23. Chang H, Qi C, Trieu Y, et al. Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 125).
24. Schop RF, Kuehl WM, Van Wier SA, et al. Waldenstrom Macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 2002; 100:2996-3001.
25. Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenström's Macroglobulinemia. Ann Oncol 2006; 17:488-94.
26. Ocio EM, Schop RF, Gonzalez B, et al. 6q deletion in Waldenström's Macroglobulinemia is associated with features of adverse prognosis. Br J Haematol 2007; 136: 80-6.
27. Morel P, Tournilhac O, Tamburini J, et al. International Waldenstrom Macroglobulinemia Prognostic Index Project. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 124).
28. Morel P, Duhamel A, Gobbi P, et al. International Prognostic scoring system for Waldenström's Macroglobulinemia. Blood 2008; Epub ahead of print.
29. Kastritis E, Zervas K, Repoussis P, et al. Prognostication in young and elderly patients with Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 127).
30. Owen R. Complexities of assessing response in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 128).
31. Ciccarelli BT, Yang G, Hatjiharissi E, et al. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab induced IgM flare, as well as plasmapheresis, in patients with Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 129).
32. Buske C, on behalf of the German Low Grade Lymphoma Study Group. CHOP versus R-CHOP in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 138).
33. Ioakimidis L, Patterson CJ, Soumerai JD, et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in patients with Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 165).
34. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom Macroglobulinemia with dexamethasone, rituximab and cyclophosphamide. J Clin Oncol 2007; 25: 3344-9.
35. Dimopoulos MA, Kastritis E, Gavriatopoulou M, et al. Rituximab based therapies in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 130).
36. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenström's Macroglobulinemia. Blood 2008; 112:4452-7.
37. Treon SP, Soumerai JD, Branagan AR, et al. Lenalidomide and rituximab in Waldenström's Macroglobulinemia. Clin Cancer Res 2008; 15:355-60.
38. Morra E. Fludarabine based combination therapies for Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 132).
39. Branagan A, Ioakimidis L, Soumerai J, et al. Long term responses to fludarabine and rituximab in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 133).
40. Barlogie B, Dhodapkar M, Crowley J. Fludarabine for Waldenström's Macroglobulinemia-A 10 year follow-up of Southwest Oncology Group (SWOG) directed intergroup trial S9003. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 145).
41. Ghielmini M. Maintenance rituximab in indolent lymphoma. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 131).
42. Chen C, Kouroukis CT, White D, et al. Bortezomib in relapsed/refractory Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 134).
43. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström's Macroglobulinemia with bortezomib, dexamethasone and rituximab: Results of WMCTG clinical trial 05-180. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 136).
44. Rummel MJ, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with Waldenström's Macroglobulinemia-First interim results of a randomized phase III study of the Study Group Indolent Lymphomas (StiL). Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 139).
45. Ghobrial I. Regulation of the PI3K/mTOR pathway in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 140).
46. Grewal I. Antibody based therapeutics targeting the TNF superfamily member CD70. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 141).
47. Advani R. Targeting CD40 in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 142).
48. Roccaro A. Novel proteasome inhibitor in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 143).
49. Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell trabsplantation for IgM amyloidosis and IgM multiple myeloma. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 148).
50. Thomas SK, Hosing C, Delasalle KB, et al. Success rates of autologous stem cell collection in patients with Waldenstrom Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Supplemental Abstract).
51. Kyriakou H, on behalf of the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Haematopoietic stem cell transplantation for Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 146).
52. Maloney D. Evidence for GVWM following mini-allo in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 147).
53. Hochberg F. Waldenström's and the Nervous System: "Bing Neel" revisited. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 151)
54. Nobile-Orazio E. Antigenic determinants in IgM paraproteinemic neuropathies. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 152).
55. Levine T. Treatment of peripheral neuropathies associated with IgM monoclonal gammopathies. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 153).
56. Fermand JP, Asli B, Brouet JC. Cutaneous manifestations of Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 154).
57. Berentsen S. Cold agglutinin mediated autoimmune hemolytic anemia in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 155).
58. Menke MN, Feke GT, McMeel JW, et al. Hyperviscosity related retinopathy in Waldenström's Macroglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 157).
59. Stone M. Hyperviscosity syndrome and cryoglobulinemia. Proceedings of the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden 2008 (Abstract 156).
60. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenström's Macroglobulinemia. J Clin Oncol 2009; 27:120-6.
61. Waldenström J: Incipient myelomatosis or "essential" hyperglobulinemia with fibrinogenopenia-A new syndrome? Acta Med Scand 1944; 216:117.